WASHINGTON (AP) — The Food and Drug Administration announced Friday it will hold a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer’s anti-smoking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback